FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: ValueSet/2.16.840.1.113762.1.4.1116.222

Packageus.nlm.vsac
Resource TypeValueSet
Id2.16.840.1.113762.1.4.1116.222
FHIR VersionR4
Sourcehttp://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1116.222/expansion
URLhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222
Version20241210
Statusactive
Date2024-12-10T01:10:30-05:00
NameAprepitantOral
TitleAprepitant Oral
Realmus
Authorityhl7
Purpose(Clinical Focus: The purpose of this value set is to represent concepts of medication Aprepitant.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Aprepitant; generic; prescribable; oral.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)

Resources that use this resource

ValueSet
2.16.840.1.113762.1.4.1116.602Neurokinin 1 Receptor Antagonist
2.16.840.1.113883.3.1444.5.245Antiemetic Agent

Resources that this resource uses

CodeSystem
rxnormRxNorm

Narrative

No narrative content found in resource


Source

{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.222",
  "meta": {
    "versionId": "14",
    "lastUpdated": "2024-12-10T01:10:30.000-05:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail": {
        "name": "American Society of Clinical Oncology Author"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate": "2025-04-08"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2024-12-10"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113762.1.4.1116.222"
    }
  ],
  "version": "20241210",
  "name": "AprepitantOral",
  "title": "Aprepitant Oral",
  "status": "active",
  "date": "2024-12-10T01:10:30-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US"
        }
      ]
    }
  ],
  "purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication Aprepitant.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Aprepitant; generic; prescribable; oral.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept": [
          {
            "code": "1729308",
            "display": "aprepitant 125 MG Powder for Oral Suspension"
          },
          {
            "code": "403810",
            "display": "aprepitant 80 MG Oral Capsule"
          },
          {
            "code": "403811",
            "display": "aprepitant 125 MG Oral Capsule"
          },
          {
            "code": "644088",
            "display": "aprepitant 40 MG Oral Capsule"
          },
          {
            "code": "754508",
            "display": "{1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:e89a8c20-642b-4938-8bf3-8fc2edd166e2",
    "timestamp": "2025-05-23T18:18:22-04:00",
    "total": 5,
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1729308",
        "display": "aprepitant 125 MG Powder for Oral Suspension"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "403810",
        "display": "aprepitant 80 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "403811",
        "display": "aprepitant 125 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "644088",
        "display": "aprepitant 40 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "754508",
        "display": "{1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack"
      }
    ]
  }
}